Our top pick for
AnaptysBio, Inc is a biotechnology business based in the US. AnaptysBio shares (ANAB) are listed on the NASDAQ and all prices are listed in US Dollars. AnaptysBio employs 89 staff and has a trailing 12-month revenue of around USD$18 million.
Since the stock market crash in March caused by coronavirus, AnaptysBio's share price has had significant positive movement.
Its last market close was USD$27.42, which is 41.06% up on its pre-crash value of USD$16.16 and 127.36% up on the lowest point reached during the March crash when the shares fell as low as USD$12.06.
If you had bought USD$1,000 worth of AnaptysBio shares at the start of February 2020, those shares would have been worth USD$867.91 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,856.33.
|Latest market close||USD$27.42|
|52-week range||USD$10 - USD$39.48|
|50-day moving average||USD$16.638|
|200-day moving average||USD$18.2575|
|Wall St. target price||USD$20.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.011|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||9.24%|
|1 month (2020-10-30)||-6.92%|
|3 months (2020-08-28)||61.96%|
|6 months (2020-05-29)||43.71%|
|1 year (2019-11-29)||103.26%|
|2 years (2018-11-30)||-63.23%|
|3 years (2017-11-30)||-67.38%|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$18 million|
|Gross profit TTM||USD$-91,338,000|
|Return on assets TTM||-12.6%|
|Return on equity TTM||-19.55%|
|Market capitalisation||USD$723.3 million|
TTM: trailing 12 months
There are currently 4.3 million AnaptysBio shares held short by investors – that's known as AnaptysBio's "short interest". This figure is 6.8% down from 4.6 million last month.
There are a few different ways that this level of interest in shorting AnaptysBio shares can be evaluated.
AnaptysBio's "short interest ratio" (SIR) is the quantity of AnaptysBio shares currently shorted divided by the average quantity of AnaptysBio shares traded daily (recently around 262124.68007313). AnaptysBio's SIR currently stands at 16.41. In other words for every 100,000 AnaptysBio shares traded daily on the market, roughly 16410 shares are currently held short.
However AnaptysBio's short interest can also be evaluated against the total number of AnaptysBio shares, or, against the total number of tradable AnaptysBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AnaptysBio's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 AnaptysBio shares in existence, roughly 160 shares are currently held short) or 0.2417% of the tradable shares (for every 100,000 tradable AnaptysBio shares, roughly 242 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AnaptysBio.
Find out more about how you can short AnaptysBio stock.
We're not expecting AnaptysBio to pay a dividend over the next 12 months.
Over the last 12 months, AnaptysBio's shares have ranged in value from as little as $10 up to $39.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AnaptysBio's is 0.7937. This would suggest that AnaptysBio's shares are less volatile than average (for this exchange).
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.